Recently the antisense oligonucleotide tofersen was approved as a disease‐modifying drug for the small subset of patients with amyotrophic lateral sclerosis (ALS) carrying a pathogenic superoxide dismutase 1 (SOD1) gene variant [1]. The gene discussed is SOD1; the disease is amyotrophic lateral sclerosis.